Greenwich LifeSciences, Inc. GLSI
are a clinical-stage biopharmaceutical company focused on our Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an
immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface
receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate
(2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. We are currently expanding Flamingo-01
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $17.2M | $15.5M | $7.7M | $6.5M | $3.6M | $1.1M | $2.6M | — |
| SG&A | $2.2M | $2.2M | $1.6M | $1.6M | $1.0M | $806.2K | $818.9K | — |
| Total operating expenses | $19.4M | $17.6M | $9.3M | $8.0M | $4.6M | $1.9M | $3.4M | — |
| Operating income | -$19.4M | -$17.6M | -$9.3M | -$8.0M | -$4.6M | -$1.9M | -$3.4M | — |
| Net income | -$19.4M | -$17.4M | -$8.9M | -$7.8M | -$4.6M | -$1.9M | -$3.4M | — |
| EPS, basic | -1.43 | -1.34 | -0.69 | -0.61 | -0.35 | — | — | — |
| EPS, diluted | -1.43 | -1.34 | -0.69 | -0.61 | -0.35 | -0.20 | -1.52 | — |
| Shares, diluted (wtd. avg.) | $13.5M | $13.0M | $12.8M | $12.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M | $6.8K | — |
| Total current assets | $6.2M | $4.1M | — | — | — | $28.7M | $6.8K | — |
| Other intangibles | — | $1.8K | $5.4K | $9.0K | $12.6K | $16.2K | $19.8K | — |
| Total assets | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M | $26.7K | — |
| Accounts payable | $4.9M | $2.8M | $256.3K | $220.8K | $220.8K | $711.0K | $730.3K | — |
| Total current liabilities | $5.8M | $3.2M | $294.4K | $262.9K | $385.2K | $1.0M | $1.4M | — |
| Total liabilities | $2.5M | $3.2M | $294.4K | $262.9K | $385.2K | $1.0M | $1.4M | — |
| Retained earnings | -$87.1M | -$67.8M | -$50.4M | -$41.5M | -$33.6M | -$29.1M | -$27.2M | — |
| Total equity | $353.2K | $908.6K | $6.7M | $13.2M | $26.8M | $27.6M | -$1.4M | -$10.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.9M | -$7.3M | -$6.5M | -$6.2M | -$4.3M | -$1.2M | -$293.3K | — |
| Stock-based compensation | $6.8M | $7.3M | $2.4M | $1.7M | $660.6K | $678.0K | $194.9K | — |
| Financing cash flow | $12.0M | $4.4M | — | -$7.5M | $2.8M | $29.8M | $215.0K | — |
| Buybacks | — | — | — | $7.5M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-026651.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |